Recent SEC filings highlight significant insider buying activity at two firms. Mark Coleman, at Axsome Therapeutics (AXSM), purchased 1,575 shares for $200,466 at $127.28 each, marking his first buy in the past year. Separately, ProFrac Holding (ACDC) Executive Chairman Matthew Wilks acquired 43,297 shares for $164,578 at $3.80, augmenting his prior substantial investments in the company. These transactions, occurring as AXSM traded down 0.5% and ACDC up 4.9% on Wednesday, typically signal executive confidence in future company performance.
Recent SEC filings reveal noteworthy insider buying activity at Axsome Therapeutics (AXSM) and ProFrac Holding (ACDC), often interpreted as a signal of executive confidence. At Axsome, Mark Coleman executed his first purchase in the past twelve months, investing $200,466 in 1,575 shares at $127.28 each. This transaction stands out as a fresh signal of conviction, occurring while the stock traded down approximately 0.5% on Wednesday, suggesting the market had not immediately priced in this development. In a separate transaction at ProFrac Holding, Executive Chairman Matthew Wilks acquired 43,297 shares for $164,578. This purchase is particularly significant as it was made at $3.80 per share, substantially below his average cost of $6.17 on prior investments totaling $1.05M over the past year, indicating a strong belief that the stock is undervalued. The market responded more favorably to this news, with ACDC's stock climbing about 4.9% on the day.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
